American Association for Cancer Research
10780432ccr203546-sup-251110_2_supp_6852818_qn3y18.docx (495.32 kB)

Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer

Download (495.32 kB)
journal contribution
posted on 2023-03-31, 23:04 authored by Ning Li, Hualei Bu, Jihong Liu, Jianqing Zhu, Qi Zhou, Li Wang, Rutie Yin, Xiaohua Wu, Shuzhong Yao, Kangsheng Gu, Hui Zhang, Guiling Li, Hongming Pan, Qiang Wu, Ruifang An, Xinfeng Yang, Yaping Zhu, Xiaoping Wan, Wei Duan, Jianping Xiong, Hongyan Guo, Ge Lou, Jing Wang, Wenjing Hu, Xin Zhang, Yuanguang Meng, Ben Zhang, Yuting Wang, Quanren Wang, Lingying Wu

Supplementary Data



Fluzoparib (PARP inhibitor) showed promising antitumor activity for advanced ovarian cancer in a phase I study. This study aimed to assess the efficacy and safety of fluzoparib in patients with germline BRCA1/2-mutated recurrent ovarian cancer. This open-label, multicenter, single-arm, phase II study enrolled patients with platinum-sensitive recurrent ovarian cancer and germline BRCA1/2 mutation who had previously received two to four lines of platinum-based chemotherapy. Fluzoparib 150 mg was administered orally twice daily. The primary endpoint was independent review committee (IRC)-assessed objective response rate per RECIST v1.1. A total of 113 patients were enrolled and received at least one dose of fluzoparib. As of data cutoff on March 21, 2020, the median follow-up period was 15.9 months (interquartile range, 13.5–18.5). The IRC- and investigator-assessed objective response rates were 69.9% [95% confidence interval (CI), 60.6–78.2] and 70.8% (95% CI, 61.5–79.0), respectively. The objective response rates were similar across all prespecified subgroups. The median IRC- and investigator-assessed progression-free survival was 12.0 months (95% CI, 9.3–13.9) and 10.3 months (95% CI, 9.2–12.0), respectively. The 12-month survival rate was 93.7% (95% CI, 87.2–96.9). Grade ≥3 adverse events occurred in 63.7% (72/113) of the patients, with the most common one being anemia/decreased hemoglobin. Adverse events that led to treatment interruption, dose reduction, and discontinuation occurred in 39.8%, 34.5%, and 0.9% of patients, respectively. One treatment-related death occurred. Fluzoparib demonstrated promising antitumor activity and acceptable safety profile in germline BRCA1/2-mutated, platinum-sensitive relapsed ovarian cancer. Thus, fluzoparib might be a novel treatment option for this population.

Usage metrics

    Clinical Cancer Research





    Ref. manager